AXSOME THERAPEUTICS, INC.

AXSM

CIK 0001579428 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$196M
↑+65.0% +$77Mvs FY2024 (Q4)
Gross Profit
$184M
↑+69.7% +$75Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
58/100
  • Profitability
    0ROIC -59.4% (10% = solid, 20%+ = moat)
  • Liquidity
    53Current Ratio 1.55 (above 1.5 = solid)
  • Leverage
    33D/E 1.33 (under 0.5 = conservative)
  • Efficiency
    63Asset Turnover 1.01x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +65.0% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -27.0% · trend +46.9pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$480K
investment in PP&E
Stock-based comp (TTM)
$94M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$690M
everything owned
Total liabilities
$602M
everything owed
Stockholders' equity
$88M
shareholder claim
Net debt
$-205M
Net cash position ($205M)

Recent performance · 45 quarters

Revenue↑+65.0% +$77M
$196M
Net Income↑+26.9% +$17M
$-47M
Free Cash Flow↓-136.7% -$41K
$-71K
Operating Margin↑+32.8pts
-27.0%

Drill down